Church & Dwight
Markets household and personal-care brands led by ARM & HAMMER, OXICLEAN, and THERABREATH.
Something off on this page? Send us feedback.
Profile
Sells household, personal-care, and over-the-counter products through a portfolio led by ARM & HAMMER, OXICLEAN, THERABREATH, WATERPIK, HERO, BATISTE, and TOUCHLAND, alongside a smaller specialty-products operation. The U.S. consumer business supplies most revenue, and major retailers—especially Walmart—concentrate distribution.
Develops and markets household and personal-care products across Consumer Domestic and Consumer International, led by ARM & HAMMER, OXICLEAN, THERABREATH, WATERPIK, HERO, BATISTE, TOUCHLAND, TROJAN, and FIRST RESPONSE. ARM & HAMMER spans laundry, cat litter, oral care, deodorizing, and baking soda, while the wider portfolio covers cleaning, oral care, skin and hair care, sexual health, home testing, and over-the-counter remedies.
Extends established brands into adjacent products, supports them with marketing and product innovation, and periodically adds or exits brands; recent moves added Touchland and Miss Mouth's while removing vitamin brands and selected smaller lines. Consumer Domestic supplies most sales, Consumer International serves subsidiary markets and export channels, and Specialty Products Division sells animal nutrition, specialty chemicals, and commercial and professional products. Sales remain concentrated among large retailers, with Walmart the largest customer.
Company facts
Categories
Key statistics
Year to date +22.5% · Average volume (30d) 1.8M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 3, 2026 | RBC Capital | Reiterate | Outperform | $114 | $115 |
| Aug 3, 2026 | Morgan Stanley | Target | $105 | $112 | |
| Aug 3, 2026 | Cowen & Co. | Reiterate | Hold | $97 | |
| Aug 3, 2026 | UBS | Reiterate | Neutral | $100 | $107 |
| Aug 3, 2026 | Jefferies | Reiterate | Buy | $102 | $115 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026Q2 FY26 | $0.90 | $0.89 | −0.7% | $1.50B | $1.53B | +1.8% | +1.16% |
| May 1, 2026Q1 FY26 | $0.93 | $0.95 | +2.2% | $1.46B | $1.47B | +0.9% | −3.26% |
| Jan 30, 2026Q4 FY25 | $0.84 | $0.86 | +2.9% | $1.64B | $1.64B | +0.3% | +1.13% |
| Oct 31, 2025Q3 FY25 | $0.74 | $0.81 | +10.1% | $1.53B | $1.59B | +3.4% | −1.61% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.47B | $1.51B | $1.59B | $1.64B | $1.47B | $1.53B | |
| Gross profit | $659.6M | $647.0M | $714.4M | $753.8M | $681.4M | $693.9M | |
| Operating income | $295.3M | $261.7M | $254.6M | $266.0M | $291.0M | $276.4M | |
| Net income | $220.1M | $191.0M | $182.2M | $143.5M | $216.3M | $202.8M | |
| Diluted EPS | $0.89 | $0.78 | $0.74 | $0.60 | $0.91 | $0.85 | |
| Gross margin | 45.0% | 43.0% | 45.1% | 45.8% | 46.4% | 45.4% | |
| Operating margin | 20.1% | 17.4% | 16.1% | 16.2% | 19.8% | 18.1% |
Fiscal years (4-quarter sums)FY21 $5.19B · FY22 $5.38B · FY23 $5.87B · FY24 $6.11B · FY25 $6.20B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $254.8M · Total debt $2.43B · Total assets $9.11B · Shareholders' equity $4.35B
Dividends
Raised for 35 straight years — most recently to $0.3075 from $0.295 in Feb 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 14, 2026 | Aug 14 | Sep 1 | $0.3075 | |
| May 15, 2026 | May 15 | Jun 1 | $0.3075 | |
| Feb 13, 2026 | Feb 13 | Mar 2 | $0.3075 | raised from $0.295 |
| Nov 14, 2025 | Nov 14 | Dec 1 | $0.295 | |
| Aug 15, 2025 | Aug 15 | Sep 2 | $0.295 | |
| May 15, 2025 | May 15 | Jun 2 | $0.295 | |
| Feb 14, 2025 | Feb 14 | Mar 3 | $0.295 | raised from $0.2838 |
| Nov 15, 2024 | Nov 15 | Dec 2 | $0.2838 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 236.94M · Float 236.39M · 99.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 22.45M | 9.47% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 15.51M | 6.54% | 13F | Aug 13, 2026 |
| State Street Corp | 14.05M | 5.93% | 13F | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 13.16M | 5.55% | 13F | Aug 13, 2026 |
| JPMorgan Chase & Co | 9.14M | 3.86% | 13F | Aug 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 26, 2026 | Carlos G. Linares | officer: EVP Chief Tech&Global New Prod | −15,375 | $103.00 |
| Aug 25, 2026 | Rene Hemsey | officer: EVP, Chief HR Officer | −5,000 | $102.26 |
| Aug 24, 2026 | Carlos G. Linares | officer: EVP Chief Tech&Global New Prod | −15,375 | $102.00 |
| Aug 11, 2026 | Bradley C. Irwin | director | −4,300 | $102.69 |
| Aug 5, 2026 | Arthur B. Winkleblack | director | −13,200 | $102.83 |
Peers
- Procter & Gamble
Broadest overlap in fabric care, home care, oral care, and grooming
- Clorox
Direct household, laundry-additive, disinfecting, and litter rival
- Colgate-Palmolive
Concentrated pressure in oral care, personal care, and home care
- Kenvue
Consumer-health and personal-care overlap across oral, OTC, and skin
- Haleon (ADR)
Oral-health and OTC-health rival with global consumer-health scale
- Unilever (ADR)
Personal-care and international home-care pressure
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Church & Dwight | $101.26 | +0.03% | $23.99B | 32.7 | 25.9 | 3.9 | +1.6% |
| Procter & Gamble | $143.75 | +0.01% | $341.75B | 21.7 | 20.5 | 3.9 | +1.5% |
| Clorox | $102.46 | −0.11% | $12.40B | 21.3 | 17.7 | 1.8 | −2.0% |
| Colgate-Palmolive | $90.85 | +0.15% | $72.62B | 36.0 | 23.1 | 3.5 | +4.9% |
| Kenvue | $19.17 | +0.03% | $36.81B | 22.0 | 16.0 | 2.4 | +3.0% |
| Haleon (ADR) | $10.11 | +0.05% | $44.52B | 20.7 | 10.8 | 2.9 | +3.7% |
| Unilever (ADR) | $63.77 | −2.01% | $140.18B | 21.7 | — | 2.6 | −17.9% |
| Median | 21.7 | 17.7 | 2.8 | +2.3% |